z-logo
Premium
β‐Receptor Selectivity of Carvedilol and Metoprolol Succinate in Patients with Heart Failure (SELECT Trial): A Randomized Dose‐Ranging Trial
Author(s) -
Zebrack James S.,
Munger Mark,
MacGregor John,
Lombardi William L.,
Stoddard Gregory P.,
Gilbert Edward M.
Publication year - 2009
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.29.8.883
Subject(s) - carvedilol , metoprolol , medicine , heart failure , digoxin , randomized controlled trial , anesthesia , pharmacology , cardiology
Study Objective. To determine whether metoprolol succinate (a β 1 ‐selective β‐blocker) remains β 1 ‐selective compared with carvedilol (a nonselective β‐blocker) during upward titration of doses in patients with American College of Cardiology (ACC) stage C heart failure. Design. Prospective, randomized, parallel‐arm study. Setting. General clinical research center. Patients. Twenty‐five β‐blocker‐naïve adults with New York Heart Association functional classes II or III heart failure (i.e., ACC stage C). Intervention. Patients received either immediate‐release carvedilol 3.125 mg twice/day or controlled‐release metoprolol succinate 25 mg once/day; doses were titrated upward by doubling the dose every 2 weeks until reaching a maximum tolerated dose or a goal dose of carvedilol 25 mg twice/day and metoprolol 200 mg/day. Before each dose titration, terbutaline (a β‐receptor agonist) was infused at 6 mg/kg over 1 hour for determination of β 2 ‐blockade. Measurements and Main Results. Patients were studied at baseline and after each dose titration of metoprolol succinate (at 25, 50, 100, and 200 mg once/day) and immediate‐release carvedilol (at 3.125, 6.25, 12.5, and 25 mg twice/day). Glucose and potassium concentrations were measured twice serially at baseline, every 10 minutes during infusion, every 15 minutes for the first hour after infusion, and every 30 minutes for the second hour after infusion. The median area under the concentration‐time curve (AUC) was calculated for changes in glucose and potassium concentrations. As assessed by glucose AUC, there was no significant difference in the degree of β 2 ‐blockade between metoprolol 200 mg and carvedilol 25 mg. In contrast to these data, the degree of β 2 ‐blockade as assessed by potassium AUC was greater for carvedilol compared with metoprolol across all doses. Conclusion. In this ACC stage C heart failure population, carvedilol was nonselective at all clinically relevant doses, whereas metoprolol succinate was β 1 ‐selective at low doses and became progressively nonselective at higher doses.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here